2024-09-25 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops, manufactures, and markets prescription medicines, vaccines, and animal health products.

**1. Performance Comparison with S&P 500:**

* **Cumulative Return:**  MRK: 79.06%, VOO: 133.37%
* **Current Divergence:** -54.31%
* **Relative Divergence:** 29.69% (This means that MRK's current performance is at the 29.69% percentile compared to its historical performance relative to VOO.) 

**2. Recent Price Action:**

* **Closing Price:** $115.02
* **5-day Moving Average:** $116.77
* **20-day Moving Average:** $116.75
* **60-day Moving Average:** $119.14

**3. Technical Indicators:**

* **RSI:** 47.25 (Neutral)
* **PPO:** 0.02 (Slight bullish momentum)
* **Delta_Previous_Relative_Divergence:** -5.81 (Short-term bearish divergence)
* **Expected Return:** 0.0% (This refers to the maximum expected return over a 5-year period based on current investment.)

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue   |
|------------|---------|-----------|
| 2024-08-05 | $2.15   | $16.11 B$ |
| 2024-05-03 | $1.88   | $15.78 B$ |
| 2023-11-03 | $1.87   | $15.96 B$ |
| 2023-08-07 | -$2.35 | $15.04 B$ |
| 2024-08-05 | -$2.35 | $15.04 B$ |

* **Most Recent Earnings:**  The latest earnings report for Q2 2024 showed an EPS of $2.15, exceeding analyst expectations of $1.88. Revenue also surpassed expectations, reaching $16.11 billion compared to the projected $15.93 billion.

**5. News and Recent Issues:**

* **Recent Market Outlook:**  While MRK has performed well in recent quarters, some analysts are concerned about the company's dependence on its Keytruda drug and the potential for competition in the immunotherapy market. 
* **Analyst Opinions:**  Overall, analysts remain optimistic about MRK's long-term prospects, citing its strong R&D pipeline and continued growth in its animal health segment. However, some investors are concerned about the company's valuation and potential for future growth.
* **Performance Highlights:**  MRK has recently seen a positive trend in its stock price, driven by strong earnings and positive analyst sentiment. However, it's important to note that the stock has underperformed the broader market in the past year. 

**6. Comprehensive Analysis:**

Merck & Co Inc shows a mixed picture. While the company has delivered strong recent earnings results and enjoys a favorable analyst outlook, its long-term performance has lagged behind the S&P 500.  Technical indicators suggest neutral to slightly bullish momentum, but the short-term bearish divergence in the relative divergence suggests potential for near-term price correction. 

**7. Recommendation:**

MRK remains a strong company with a solid track record in the pharmaceutical industry. However, the current market environment, along with potential competition, may create challenges in the short term. Investors should monitor the company's financial performance and the broader market conditions before making investment decisions. 
